Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor.
(Reuters Health) - Women with silicone breast implants may have a higher risk of certain medical problems than women who don't get implants, but more research is needed to get a complete picture of implant safety over the long term, a new U.S. study suggests.
The U.S. Food and Drug Administration has rejected Novartis's bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors, the Swiss drugmaker said on Thursday.
(Reuters Health) - Even though many people swear by fitness trackers to help lose weight and stay in shape, a review of existing research confirms that many of these gadgets are not very good at measuring how much energy we burn.
French foie gras makers, still recovering from two severe bird flu crises that ravaged flocks, said on Thursday they would be able to face any new outbreak thanks to strict security measures but prices will remain high to make up for increased costs.
U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and will grant the Germany-based company non-exclusive marketing rights for the drug.
(Reuters Health) - New mothers who want intrauterine devices (IUDs) for long-acting contraception after giving birth should know the risk of the implant being expelled is tied to how soon after delivery it is inserted, researchers say.
(Reuters Health) - For people with diabetes, the chance of developing eye damage that can lead to blindness may depend on how many hours per day they can keep their blood sugar levels under control, a Chinese study suggests.
Republicans could try again to repeal Obamacare if they win enough seats in U.S. elections next month, Senate Republican Leader Mitch McConnell said on Wednesday, calling a failed 2017 push to repeal the healthcare law a "disappointment."
Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers.